CRANBURY, N.J., Dec. 19 /PRNewswire-FirstCall/ -- Amicus Therapeutics Inc. (Nasdaq: FOLD), a biopharmaceutical company developing small-molecule, orally administered pharmacological chaperones for the treatment of human genetic diseases, announced today positive results from its recently completed Phase 2 clinical trials of Amigal(TM) (migalastat hydrochloride) for Fabry disease. As of November 2007, Amigal is being developed in partnership with Shire Human Genetic Therapies (HGT), a business unit of Shire plc, which is focused on genetic diseases. The results will be discussed as a part of an "R&D Day" meeting being hosted by the company today from 4:30 to 7:00 PM at the Four Seasons Hotel in New York City. A live audio web cast of the presentation will be available to all interested parties through the Company's website at http://www.amicustherapeutics.com. Interested parties should connect at least 15 minutes prior to the presentation to ensure adequate time for any software download that may be required to join the webcast. An archive of the webcast will be available at the same address until approximately January 2, 2008.
"The completion of these trials is a major milestone for Amicus and these clinical results represent an important proof of concept for the pharmacological chaperone platform technology," said John F. Crowley, President and CEO of Amicus Therapeutics. "We look forward to advancing our program in Fabry as well as Gaucher, Pompe, and other important therapeutic targets utilizing this new approach to the treatment of a wide range of human genetic diseases."
Summary of Study Results:
The primary objective of the Phase 2 trials was to evalu
|SOURCE Amicus Therapeutics Inc.|
Copyright©2007 PR Newswire.
All rights reserved